Antibodies, Fc receptors and cancer.

Since the first report of the successful use of a monoclonal antibody for the treatment of human B cell lymphoma in 1982, several antibodies have become incorporated into standard treatment protocols for cancer. One of the most important factors that determine antibody activity in vivo is the efficient interaction with cellular Fc-receptors on innate immune effector cells. It has become clear that the outcome of this interaction is influenced by several factors, such as the antibody isotype-specific affinity to activating and inhibitory receptors, the level of inhibitory FcgammaRIIB expression, and the composition of the sugar side chain attached to the antibody Fc-portion. These novel insights into antibody FcR interactions might be useful to produce the next generation of improved immunotherapeutic molecules.

• Publication year

  2007

• Venue

  Current Opinion in Immunology

• Publication date

  2007-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.COI.2007.01.005PMID 17291742
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

  2006cited by this paper
• The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.

  2006cited by this paper
• Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy

  2006cited by this paper
• Considering Therapeutic Antibodies

  2006cited by this paper
• Immunology. Considering therapeutic antibodies.

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Potent antibody therapeutics by design

  2006cited by this paper
• The Carbohydrate at FcγRIIIa Asn-162

  2006cited by this paper
• Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.

  2006cited by this paper
• Immune Complex-Loaded Dendritic Cells Are Superior to Soluble Immune Complexes as Antitumor Vaccine1

  2006cited by this paper
• Engineered antibody Fc variants with enhanced effector function.

  2006cited by this paper
• Fcgamma receptors: old friends and new family members.

  2006cited by this paper
• The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma.

  2006cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• FcγRIV : A novel FcR with distinct IgG subclass specificity

  2005cited by this paper
• Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

  2005cited by this paper
• Human antibodies from transgenic animals

  2005cited by this paper
• Cell surface recycling of internalized antigen permits dendritic cell priming of B cells.

  2005cited by this paper
• Monoclonal antibody therapy of cancer.

  2005cited by this paper
• Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

  2005cited by this paper
• IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

  2005cited by this paper
• FcgammaRIV: a novel FcR with distinct IgG subclass specificity.

  2005cited by this paper
• Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.

  2005cited by this paper
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

  2005cited by this paper
• Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

  2005cited by this paper
• Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.

  2005cited by this paper
• Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia

  2004cited by this paper
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

  2004cited by this paper
• Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma

  2004cited by this paper
• Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.

  2004cited by this paper
• TCR Vaccines against a Murine T Cell Lymphoma: A Primary Role for Antibodies of the IgG2c Class in Tumor Protection1

  2004cited by this paper
• Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Immunotherapy: past, present and future

  2003cited by this paper
• The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*

  2003cited by this paper
• Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.

  2003cited by this paper
• More Is Not Necessarily Better: Prozone-Like Effects in Passive Immunization with IgG1

  2003cited by this paper
• Monoclonal antibody therapy for cancer.

  2003cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses.

  2002cited by this paper
• Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells

  2002cited by this paper
• Increased Efficacy of the Immunoglobulin G2a Subclass in Antibody-Mediated Protection against Lactate Dehydrogenase-Elevating Virus-Induced Polioencephalomyelitis Revealed with Switch Mutants

  2002cited by this paper
• FcγRI-Deficient Mice Show Multiple Alterations to Inflammatory and Immune Responses

  2002cited by this paper
• Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity*

  2002cited by this paper
• FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.

  2002cited by this paper
• Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• Inflammation in autoimmunity: receptors for IgG revisited.

  2001cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Immune inhibitory receptors.

  2000cited by this paper
• Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antierythrocyte Autoantibody Is Based on Their Capacity to Interact in Vivo with the Low-Affinity Fcγ Receptor III

  2000cited by this paper
• Monoclonal antibody therapy of cancer

  1999cited by this paper
• Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization

  1999cited by this paper
• Fc receptors are required in passive and active immunity to melanoma.

  1998cited by this paper
• Divergent roles for Fc receptors and complement in vivo.

  1998cited by this paper
• Fc receptors.

  1997cited by this paper
• Immunoglobulin G–mediated Inflammatory Responses Develop Normally in Complement-deficient Mice

  1996cited by this paper
• Cytotoxic antibodies trigger inflammation through Fc receptors.

  1995cited by this paper
• Agalactosyl glycoforms of IgG autoantibodies are pathogenic.

  1994cited by this paper
• Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide

  1990cited by this paper
• IgG2a restriction of murine antibodies elicited by viral infections

  1987cited by this paper
• Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

  1986cited by this paper
• Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.

  1986cited by this paper
• Importance of immunoglobulin isotype in human antibody-dependent, cell- mediated cytotoxicity directed by murine monoclonal antibodies

  1985cited by this paper

• Optimization of a U937 cell-based reporter system to assess ADCC activity of ustekinumab versus trastuzumab.

  2026cites this paper
• The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis

  2025cites this paper
• Transcriptional cyclin-dependent kinases Cdk8 and Cdk19 are required for normal macrophage differentiation

  2025cites this paper
• The function of antibodies

  2024cites this paper
• Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B.

  2024cites this paper
• Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study

  2024cites this paper
• Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer

  2024cites this paper
• The current landscape of optogenetics for the enhancement of adoptive T-cell therapy

  2024cites this paper
• Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation

  2023cites this paper
• The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer

  2023cites this paper
• Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions

  2022cites this paper
• Notch1 and Notch4 core binding domain peptibodies exhibit distinct ligand-binding and anti-angiogenic properties

  2022cites this paper
• Biophysics involved in the process of tumor immune escape

  2022cites this paper
• Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody

  2022cites this paper
• Functional Characterization of Largemouth Bass (Micropterus salmoides) Soluble FcγR Homolog in Response to Bacterial Infection

  2022influential citation
• FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma

  2022cites this paper
• The role of Syk phosphorylation in Fc receptor mediated mIgM+ B lymphocyte phagocytosis in flounder (Paralichthys olivaceus).

  2022cites this paper
• Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer

  2022influential citation
• Regulatory Role of Fc Receptor in mIgM+ B Lymphocyte Phagocytosis in Flounder (Paralichthys olivaceus)

  2021cites this paper
• Engineering Antibody-Based Therapeutics: Progress and Opportunities

  2021cites this paper
• Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent

  2021cites this paper
• CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies

  2021cites this paper
• Advancements in mRNA Encoded Antibodies for Passive Immunotherapy

  2021cites this paper
• Therapeutic exploitation of neutrophils to fight cancer.

  2021cites this paper
• Mechanismen der IgG-Aktivität in der Therapie von Autoimmunität und Krebs

  2021cites this paper
• Evaluating single-domain antibodies as carriers for targeted vaccine delivery to the small intestinal epithelium.

  2020cites this paper
• Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.

  2020cites this paper
• Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes

  2020cites this paper
• Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine

  2020cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2020cites this paper
• Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.

  2020cites this paper
• Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential

  2020cites this paper
• Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering

  2020cites this paper
• IgA: Structure, Function, and Developability

  2019cites this paper
• Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

  2019cites this paper
• Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

  2019cites this paper
• Glycosylation as an Important Regulator of Antibody Function

  2019cites this paper
• Boosting therapeutic potency of antibodies by taming Fc domain functions

  2019cites this paper
• Bispecific antibodies: Potential immunotherapies for HIV treatment.

  2019cites this paper
• Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression

  2019cites this paper
• An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

  2019cites this paper
• Synergy between Th1 and Th2 responses during Mycobacterium tuberculosis infection: A review of current understanding

  2019cites this paper
• Disease‐Specific IgG Fc Glycosylation Ratios as Personalized Biomarkers to Differentiate Non‐Small Cell Lung Cancer from Benign Lung Diseases

  2019cites this paper
• Monoclonal antibody‐mediated killing of tumour cells by neutrophils

  2018cites this paper
• The promise and challenges of immune agonist antibody development in cancer

  2018cites this paper
• Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types.

  2018cites this paper
• IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages

  2018cites this paper
• Improving Immunotherapy Through Glycodesign

  2018cites this paper
• A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle

  2018cites this paper
• Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.

  2018cites this paper
• The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer

  2018cites this paper
• Fcγ Receptor Heterogeneity in Leukocyte Functional Responses

  2017cites this paper
• Antibody production by in vivo RNA transfection

  2017cites this paper
• Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields

  2017cites this paper
• Control of Phagocytosis by Microbial Pathogens

  2017cites this paper
• Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

  2017cites this paper
• Chapter 2 Bispecific Antibodies from Hybrid Hybridoma

  2017cites this paper
• Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.

  2017cites this paper
• Fc Gamma R

  2017cites this paper
• Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients

  2017cites this paper
• Large scale ex vivo expansion of clinical-grade effector cells for adoptive immunotherapy.

  2017cites this paper
• Antibody Drug Conjugates for Cancer Therapy

  2017cites this paper
• Inhibition of glycosylation on a camelid antibody uniquely affects its Fc&ggr;RI binding activity

  2017cites this paper
• A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries

  2017cites this paper
• An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity

  2017cites this paper
• Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity

  2016cites this paper
• Immune Cells in Cancer Therapy and Drug Delivery

  2016cites this paper
• Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy

  2016cites this paper
• Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

  2016cites this paper
• Differential Effects of Alternative Glycoforms of IgG on Human Monocytes and Macrophages: Sialylated IgG Induces Novel Expression Signatures of Cell Surface Markers, Cytokines, and Chemokines

  2016cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2015cites this paper
• Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity

  2015cites this paper
• TIM-3 Is a Novel Therapeutic Target for Eradicating Acute Myelogenous Leukemia Stem Cells

  2015cites this paper
• Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo

  2015cites this paper
• Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications

  2015cites this paper
• This information is current as Receptors γ and Human Fc Monoclonal Antibodies Specific for Mouse Development and Characterization of Beers and

  2015cites this paper
• FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.

  2015cites this paper
• Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.

  2015cites this paper
• IgE immunotherapy against cancer.

  2015cites this paper
• IgE Antibodies: Generation and Function

  2015cites this paper
• Impact of target antigen properties on antibody effector mechanisms

  2015cites this paper
• Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions

  2015cites this paper
• Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.

  2015cites this paper
• B cells drive Th2 responses by instructing human dendritic cell maturation

  2015cites this paper
• Structural analysis of Fc/FcγR complexes: a blueprint for antibody design

  2015cites this paper
• Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors

  2015cites this paper
• Fcγ receptors: genetic variation, function, and disease

  2015cites this paper
• Structural mechanism of high affinity FcγRI recognition of immunoglobulin G

  2015cites this paper
• Fcγ receptor pathways during active and passive immunization

  2015cites this paper
• Anti-tumor and immunomodulatory activity of iron hepta-tungsten phosphate oxygen clusters complex.

  2015cites this paper
• Fc glycans of therapeutic antibodies as critical quality attributes

  2015cites this paper
• Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer

  2015cites this paper
• Optimisation of the Lister strain of vaccinia virus for use as an anticancer immunotherapeutic agent

  2015cites this paper
• Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

  2015cites this paper
• Computational Methods in the Optimization of Biologic Modalities

  2015cites this paper
• Tumor Cell Targeting by Iron Oxide Nanoparticles Is Dominated by Different Factors In Vitro versus In Vivo

  2015cites this paper
• The role of Fc–FcγR interactions in IgG-mediated microbial neutralization

  2015cites this paper
• Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.

  2014cites this paper
• Engineering therapeutic proteins for immune modulation

  2014cites this paper
• Increased Sialylation of Anti-Thomsen-Friedenreich Antigen (CD176) Antibodies in Patients with Gastric Cancer: A Diagnostic and Prognostic Potential

  2014cites this paper